Search
Ambrisentan
go.drugbank.com/drugs/DB06403ApprovedInvestigationalStudies establishing the efficacy of Ambrisentan included patients with both idiopathic or heritable pulmonary arterial hypertension and those with pulmonary arterial hypertension associated with connective … Patients studied displayed symptoms and etiologies predominantly of WHO Functional Class II-III.
Products: INFINIX® 5 MG, VOLIBRIS 5 MGBaloxavir marboxil
go.drugbank.com/drugs/DB13997ApprovedInvestigational[A39895, A251755] It is a prodrug of [baloxavir] [L42855] with an improved absorption profile than its active metabolite due to the addition of a phenolic hydroxyl group to its structure. … [L4779] It was also approved by the European Commission on January 7, 2021.[L45241]
Products: XOFLUZA 20 MG FİLM KAPLI TABLET, 2 ADET, XOFLUZA 20 MG FİLM KAPLI TABLET, 4 ADETIloprost
go.drugbank.com/drugs/DB01088ApprovedInvestigational[A263326] Iloprost consists of a mixture of the 4R and 4S diastereoisomers at a ratio of approximately 53:47.[L50146] It is a potent vasodilator with reported anti-thrombotic properties. … Iloprost is an analog of prostacyclin (PGI2; epoprostenol), an endogenous prostanoid mainly produced in the vascular endothelium. It is more stable than prostacyclin, which is short-lived.
Products: Ilomedin 10 µg/0,5 ml - Infusionslösungskonzentrat, Ilomedin 50 µg/0,5 ml - InfusionslösungskonzentratCalcifediol
go.drugbank.com/drugs/DB00146ApprovedInvestigationalNutraceuticalThe major circulating metabolite of vitamin D3 (cholecalciferol). It is produced in the liver and is the best indicator of the body's vitamin D stores. … It is effective in the treatment of rickets and osteomalacia, both in azotemic and non-azotemic patients. Calcifediol also has mineralizing properties.
Products: HIDROFEROL® 0.266 MG CÁPSULAS BLANDASTuroctocog alfa
go.drugbank.com/drugs/DB09109ApprovedTuroctocog alfa is produced in Chinese hamster ovary (CHO) cells without addition of any human- or animal-derived materials. … process allowing isolation of the intact rFVIII.
Tranexamic acid
go.drugbank.com/drugs/DB00302ApprovedInvestigationalTranexamic acid is a synthetic derivative of [lysine] used as an antifibrinolytic in the treatment and prevention of major bleeding. … It possesses a similar mechanism of action to [aminocaproic acid] but is approximately 10-fold more potent.
Products: ACIDO TRANEXAMICO EG, TRANEXAM® 500 MGKanamycin
go.drugbank.com/drugs/DB01172ApprovedInvestigationalVet approvedWithdrawnKanamycin (also known as kanamycin A) is an aminoglycoside bacteriocidal antibiotic, available in oral, intravenous, and intramuscular forms, and used to treat a wide variety of infections.
Products: KANAMYCIN SULFATE INJECTION 1 g/3 ml, KANAMYCIN MEIJI FOR INJECTION 1 g/vialTinzaparin
go.drugbank.com/drugs/DB06822ApprovedInvestigationalTinzaparin is composed of molecules with and without a special site for high affinity binding to antithrombin III (ATIII). This complex greatly accelerates the inhibition of factor Xa. … It is a heterogeneous mixture of with an average molecular weight between 5500 and 7500 daltons.
Products: INNOHEP INYECTABLE VIAL 2 MG 10.000 UI/ML.Depemokimab
go.drugbank.com/drugs/DB18846ApprovedInvestigational[A275338] Approved by the FDA on December 16, 2025, depemokimab is indicated as an add-on maintenance treatment for severe asthma characterized by an eosinophilic phenotype in adult and paediatric patients … [A275338, L54758] Its long duration of action is granted by seven amino acid substitutions in the heavy chain sequence.
Almonertinib
go.drugbank.com/drugs/DB16640ApprovedInvestigational[A231859] On March 19, 2020, almonertinib was approved in China for the treatment of EGFR T790M+ non-small cell lung cancer.[A231864] Almonertinib was also approved by the EMA on February 20, 2026. … [A231859, A231864, A231869] Unlike other third-generation EGFR TKIs, almonertinib is a pyrimidine-based drug that forms a covalent bond to the binding site of the EGFR tyrosine kinase domain.